ASPI's Q3 Loss Widens to $96.4M Amid Convertible Note Fair Value Hit

Ticker: ASPI · Form: 10-Q · Filed: Nov 19, 2025 · CIK: 1921865

Sentiment: bearish

Topics: Isotopes, Nuclear Energy, Biotechnology, Financial Performance, Convertible Debt, Acquisitions, SEC Filing

Related Tickers: ASPI, SKBL

TL;DR

**ASPI is burning cash at an alarming rate, with a massive convertible note fair value hit overshadowing revenue growth; steer clear until they prove profitability.**

AI Summary

ASP Isotopes Inc. reported a significant increase in total assets to $225,890,161 as of September 30, 2025, up from $94,347,988 at December 31, 2024, primarily driven by a substantial rise in cash and cash equivalents to $113,942,156 from $61,890,048. The company's revenue for the nine months ended September 30, 2025, more than doubled to $7,189,476 from $2,950,348 in the prior year, largely due to the introduction of $3,618,868 in construction services revenue. Despite revenue growth, the net loss attributable to shareholders widened dramatically to $96,383,061 for the nine-month period, compared to a net loss of $25,931,908 in the same period of 2024. This increased loss was primarily due to a massive negative change in the fair value of convertible notes payable, totaling $(64,542,295) for the nine months ended September 30, 2025. Operating expenses also surged, with selling, general and administrative expenses reaching $30,701,750 for the nine months, up from $17,976,882. The company's strategic outlook includes the potential Renergen acquisition and the listing of Quantum Leap Energy, both subject to significant closing conditions and regulatory approvals by November 28, 2025.

Why It Matters

This filing reveals a company in a high-growth, high-risk phase, with significant capital raises and strategic acquisitions like Skyline Builders Group Holding Limited and the potential Renergen acquisition. While revenue is growing, the substantial net loss, primarily from the fair value adjustment of convertible notes, signals volatility and potential dilution for investors. Employees might see increased opportunities with expansion, but also face uncertainty given the company's significant losses. Customers could benefit from expanded offerings if acquisitions are successful. The broader market will watch ASPI's ability to integrate these acquisitions and achieve profitability in the competitive isotopes and energy sectors.

Risk Assessment

Risk Level: high — The company reported a net loss of $96,383,061 for the nine months ended September 30, 2025, a significant increase from $25,931,908 in the prior year. This is largely driven by a $(64,542,295) change in the fair value of convertible notes payable. Additionally, the company's ability to complete the Renergen acquisition and list Quantum Leap Energy is contingent on fulfilling numerous closing conditions by November 28, 2025, introducing substantial execution risk.

Analyst Insight

Investors should exercise extreme caution and consider avoiding ASPI stock given the substantial net losses and the significant impact of convertible note fair value adjustments. Monitor the progress of the Renergen acquisition and Quantum Leap Energy listing closely, as failure to meet the November 28, 2025 deadline could further destabilize the company's financial position and strategic direction.

Financial Highlights

debt To Equity
N/A
revenue
$7,189,476
operating Margin
N/A
total Assets
$225,890,161
total Debt
$97,900,000
net Income
-$96,383,061
eps
-$1.27
gross Margin
N/A
cash Position
$113,942,156
revenue Growth
+143.7%

Revenue Breakdown

SegmentRevenueGrowth
Construction Services$3,618,868+N/A%
Other Revenue$3,570,608+N/A%

Key Numbers

Key Players & Entities

FAQ

What were ASP Isotopes Inc.'s total revenues for the nine months ended September 30, 2025?

ASP Isotopes Inc.'s total revenues for the nine months ended September 30, 2025, were $7,189,476. This represents a substantial increase from $2,950,348 reported for the same period in 2024, largely due to the addition of $3,618,868 in construction services revenue.

Why did ASP Isotopes Inc.'s net loss increase significantly in the nine months ended September 30, 2025?

ASP Isotopes Inc.'s net loss increased significantly to $96,383,061 for the nine months ended September 30, 2025, primarily due to a negative change in the fair value of convertible notes payable, which amounted to $(64,542,295). Additionally, selling, general and administrative expenses rose to $30,701,750 from $17,976,882 in the prior year.

What is the status of ASP Isotopes Inc.'s potential Renergen acquisition?

ASP Isotopes Inc.'s ability to complete the Renergen acquisition is contingent on fulfilling a number of closing conditions, including various regulatory approvals and third-party consents, by no later than November 28, 2025, unless extended. The company also advanced $30,000,000 to Renergen under a loan agreement.

How much cash and cash equivalents did ASP Isotopes Inc. have as of September 30, 2025?

As of September 30, 2025, ASP Isotopes Inc. had $113,942,156 in cash and cash equivalents. This is a significant increase from $61,890,048 reported at December 31, 2024.

What are the key risks highlighted in ASP Isotopes Inc.'s 10-Q filing?

Key risks include the ability to achieve or sustain positive cash flows, successfully operate isotope enrichment plants, obtain regulatory approvals for enrichment, and execute strategic initiatives like the Renergen acquisition. The company also faces risks related to the extensive costs and uncertainty of new technology development and its ability to obtain funding for operations.

What was the impact of noncontrolling interests on ASP Isotopes Inc.'s financial statements?

Noncontrolling interests in consolidated subsidiaries increased significantly to $22,535,460 as of September 30, 2025, from $3,267,948 at December 31, 2024. This increase includes the fair value of noncontrolling interest at the acquisition of Skyline, which contributed $19,761,799.

How many shares of common stock did ASP Isotopes Inc. have outstanding as of November 19, 2025?

As of November 19, 2025, ASP Isotopes Inc. had 110,840,122 shares of common stock, $0.01 par value per share, outstanding. This is an increase from 93,376,629 shares issued and outstanding as of September 30, 2025.

What is ASP Isotopes Inc.'s strategy regarding Quantum Leap Energy?

ASP Isotopes Inc. is working towards completing the listing of Quantum Leap Energy as a standalone public company. This initiative is subject to various closing conditions and regulatory approvals, similar to the Renergen acquisition.

What was ASP Isotopes Inc.'s gross profit for the nine months ended September 30, 2025?

ASP Isotopes Inc.'s gross profit for the nine months ended September 30, 2025, was $1,322,116. This is an increase from $993,875 for the same period in 2024, reflecting the growth in total revenue.

What is the significance of the November 28, 2025, date for ASP Isotopes Inc.?

November 28, 2025, is the anticipated deadline for ASP Isotopes Inc. to complete the Renergen acquisition by fulfilling or obtaining a waiver of a number of closing conditions, including various regulatory approvals and third-party consents, unless extended. This date is critical for the company's strategic plans.

Risk Factors

Industry Context

ASP Isotopes Inc. operates in a specialized sector, likely involving isotopes for medical, industrial, or research applications. The company's recent performance indicates a shift towards new service-based revenue streams alongside its core operations. The competitive landscape is likely characterized by high barriers to entry due to technological expertise and regulatory hurdles.

Regulatory Implications

The company faces significant regulatory hurdles related to its strategic initiatives, including the Renergen acquisition and the potential listing of Quantum Leap Energy. Securing necessary approvals by the November 28, 2025 deadline is critical for these growth plans.

What Investors Should Do

  1. Monitor the outcome of the Renergen acquisition and Quantum Leap Energy listing approvals by November 28, 2025, as these are key strategic catalysts.
  2. Analyze the sustainability of the new construction services revenue stream and its contribution to future profitability.
  3. Assess the impact of convertible note fair value fluctuations on future earnings and the company's capital structure.
  4. Evaluate the increasing operating expenses, particularly SG&A, and management's strategy to control costs.
  5. Consider the potential dilution from the reported 110,840,122 shares outstanding as of November 19, 2025.

Key Dates

Glossary

Convertible Notes Payable
Debt instruments that can be converted into a predetermined amount of the issuer's equity at certain times. (The fair value changes of these notes significantly impacted the company's net loss, highlighting financial risk.)
Noncontrolling Interests
The portion of equity interest in a subsidiary that is not attributable to the parent company. (An increase in noncontrolling interests suggests consolidation of new entities, impacting overall financial statements.)
Fair Value
The price that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants. (Fluctuations in the fair value of financial instruments like convertible notes can lead to significant gains or losses.)

Year-Over-Year Comparison

ASP Isotopes Inc. has demonstrated substantial asset growth, with total assets more than doubling from $94.3M to $225.9M, largely due to an increased cash position. Revenue has also more than doubled to $7.19M, driven by new construction services. However, this growth has been overshadowed by a dramatic widening of the net loss to $96.4M, primarily due to a significant negative change in the fair value of convertible notes payable and increased operating expenses. The company's financial performance shows a concerning trend of escalating losses despite revenue expansion.

Filing Stats: 4,250 words · 17 min read · ~14 pages · Grade level 20 · Accepted 2025-11-19 16:31:06

Key Financial Figures

Filing Documents

Financial Statements (Unaudited)

Financial Statements (Unaudited) 5 Condensed Consolidated Balance Sheets as of September 30, 2025 and December 31, 2024 5 Condensed Consolidated Statements of Operations and Comprehensive Loss for the Three and Nine Month Periods ended September 30, 2025 and 2024 6 Condensed Consolidated Statements of Changes in Stockholders' Equity for the Three and Nine Month Periods ended September 30, 2025 and 2024 7 Condensed Consolidated Statements of Cash Flows for the Nine Month Periods ended September 30, 2025 and 2024 9 Notes to Unaudited Condensed Consolidated Financial Statements 10 Item 2.

Management's Discussion and Analysis of Financial Condition and Results of Operations

Management's Discussion and Analysis of Financial Condition and Results of Operations 35 Item 3.

Quantitative and Qualitative Disclosures About Market Risk

Quantitative and Qualitative Disclosures About Market Risk 46 Item 4.

Controls and Procedures

Controls and Procedures 46 PART II. OTHER INFORMATION 47 Item 1.

Legal Proceedings

Legal Proceedings 47 Item 1A.

Risk Factors

Risk Factors 47 Item 2. Unregistered Sales of Equity Securities and Use of Proceeds 48 Item 3. Defaults Upon Senior Securities 48 Item 4. Mine Safety Disclosures 48 Item 5. Other Information 48 Item 6. Exhibits 49

Signatures

Signatures 50 2 SPECIAL NOTE REGARDING FORWARD-LOOKING STATEMENTS This Quarterly Report on Form 10-Q contains forward-looking statements within the meaning of the federal securities laws. All statements other than statements of historical fact contained in this Quarterly Report on Form 10-Q, including statements regarding our future results of operations and financial position, business strategy and plans and objectives of management for future operations, are forward-looking statements. These statements involve known and unknown risks, uncertainties and other important factors that may cause our actual results, performance or achievements to be materially different from any future results, performance or achievements expressed or implied by the forward-looking statements. In some cases, you can identify forward-looking statements by terms such as "may," "should," "would," "expects," "plans," "anticipates," "could," "intends," "target," "projects," "contemplates," "believes," "estimates," "predicts," "potential" or "continue" or the negative of these terms or other similar expressions. The forward-looking statements in this Quarterly Report on Form 10-Q are only predictions. We have based these forward-looking statements largely on our current expectations and projections about future events and financial trends that we believe may affect our business, financial condition and results of operations. These forward-looking statements speak only as of the date of this Quarterly Report on Form 10-Q and are subject to a number of risks, uncertainties and assumptions described in the section titled "Risk Factors" and elsewhere in this Quarterly Report on Form 10-Q. Because forward-looking statements are inherently subject to risks and uncertainties, some of which cannot be predicted or quantified, you should not rely on these forward-looking statements as predictions of future events. The events and circumstances reflected in our forward-looking statements may no

-FIN ANCIAL INFORMATION

PART I-FIN ANCIAL INFORMATION

Finan cial Statements

Item 1. Finan cial Statements. ASP Isotopes Inc. Condensed Conso lidated Balance Sheets (unaudited) September 30, 2025 December 31, 2024 Assets Current assets: Cash and cash equivalents $ 113,942,156 $ 61,890,048 Accounts receivable 17,425,680 706,925 Inventories 1,371,738 65,655 Receivable from noncontrolling interests — 27,556 Note receivable 31,189,144 — Lease receivable - current 16,733 — Prepaid expenses and other current assets 10,099,525 3,053,478 Total current assets 174,044,976 65,743,662 Property and equipment, net 30,930,235 22,354,377 Operating lease right-of-use assets, net 971,658 1,122,134 Deferred tax assets 68,008 31,847 Intangible assets 1,190,562 — Goodwill 6,849,119 3,168,101 Lease receivable - noncurrent 410,223 — Equity method investments 1,322,900 — Other investments 5,000,000 — Other noncurrent assets 5,102,480 1,927,867 Total assets $ 225,890,161 $ 94,347,988 Liabilities and stockholders' equity Current liabilities: Accounts payable $ 3,424,698 $ 1,021,393 Accrued expenses 3,655,761 2,275,681 Debt - current 12,401,279 939,110 Finance lease liabilities – current 166,459 125,862 Operating lease liabilities – current 468,569 557,676 Deferred revenue 882,000 882,000 Due to related parties 3,438,275 — Other current liabilities 3,666,092 1,256,549 Share liability 220,635 — Total current liabilities 28,323,768 7,058,271 Deferred tax liabilities 307,807 — Convertible notes payable, at fair value 97,975,479 33,433,184 Debt - noncurrent 1,534,686 1,441,286 Finance lease liabilities – noncurrent 492,103 560,328 Operating lease liabilities – noncurrent 617,988 688,479 Other noncurrent liabilities 34,353 — Total liabilities 129,286,184 43,181,548 Commitments and contingencies (Note 9) Stockholders' equity Preferr

View Full Filing

View this 10-Q filing on SEC EDGAR

View on Read The Filing